The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Related News Articles

Headline
The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize the availability of vital…
Headline
Baxter Jan. 28 announced that IV solutions production has been restarted on all manufacturing lines at its North Carolina site impacted by Hurricane Helene in…
Headline
Baxter notified customers on Jan. 22 that allocations for two sodium chloride IV solutions have been increased to 100%. According to Baxter, the products will…
Headline
After incurring damage from Hurricane Helene on Sept. 27, Baxter reports that as of Dec. 19, nearly all of its manufacturing lines in its North Cove, N.C…
Headline
Baxter has resumed production on all of its 3-liter irrigation and peritoneal dialysis solutions manufacturing lines, the company announced Dec. 5. The company…
Headline
The Food and Drug Administration Dec. 4 announced empty IV bags have been added to its Medical Device Shortages List, and that the shortage is estimated to…